

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州启明醫療器械股份有限公司  
**Venus Medtech (Hangzhou) Inc.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2500)**

**INSIDE INFORMATION ANNOUNCEMENT  
ACCEPTANCE BY CSRC TO PROCESS THE COMPANY'S APPLICATION  
FOR THE FULL CIRCULATION OF SHARES**

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement (the “**Announcement**”) of the Company dated June 15, 2020 in relation to the Company's application for the full circulation of its shares. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to inform the shareholders and potential investors of the Company that it has obtained from the China Securities Regulatory Commission (the “**CSRC**”) an official acceptance letter (the “**Acceptance Letter**”) in respect of the Application on June 19, 2020. Pursuant to the Acceptance Letter, the application materials were complete and the CSRC had accepted and will process the Application.

As at the date of this announcement, details of the implementation plan of the conversion of certain domestic shares and unlisted foreign shares into H Shares that are eligible to be listed and traded on the Main Board of the Stock Exchange (the “**Conversion**”) have not been finalised and the Company has not received the approval from the CSRC in respect of the Application. The Company will make further announcements on the progress and details of the Application as and when appropriate.

**The Conversion is subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other relevant onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Venus Medtech (Hangzhou) Inc.**  
**Min Frank Zeng**  
Chairman

Hangzhou, June 22, 2020

*As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.*